Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 6,824,972

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,824,972
Title: Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-.kappa.B) activation
Abstract:Incontinentia Pigmenti (IP) is a neurocutaneous genodermatosis that segregates as an X-linked dominant disorder with a high probability of prenatal male lethality. A locus in Xq28 containing NF-.kappa.B Essential Modulator, a gene product involved in the activation of NF-kB and central to many pro-inflammatory and apoptotic pathways, contains mutations in the majority of cases of IP. Disclosed are methods, compositions and kits directed to a defect in a NF-.kappa.B related disease such as IP.
Inventor(s): Kenwrick; Sue J. (Cambridge, GB), Woffendin; Hayley (Cambridge, GB), Munnich; Arnold (Paris, FR), Smahi; Asmae (Saint Ouen, FR), Israel; Alain (Paris, FR), Poustka; Annemarie (Heidelberg, 69120, DE), Heiss; Nina (Heidelberg, 69115, DE), D\'Urso; Michele (Naples, IT), Lewis; Richard A. (Houston, TX), Nelson; David L. (Houston, TX), Aradhya; Swaroop (Houston, TX), Levy; Moise (Houston, TX)
Assignee: Baylor College of Medicine (Houston, TX) Cambridge University Technical Services Limited (Cambridge, GB) Consiglio Nazionale Delle Richerche (Rome, IT) INSERM (Cedex 13, FR) L\'Institut Pasteur (Paris, FR) Poustka; Annemarie (Heidelberg, DE) Heiss; Nina (Heidelberg, DE)
Application Number:09/863,049
Patent Claims:see list of patent claims

Details for Patent 6,824,972

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2020-05-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2020-05-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.